ArticleMedComm2026
Bispecific NK-Cell Engager Targeting TP53 Mutation Through Integration of a TCR-mimic Antibody.
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells are valuable for cancer immunotherapy because they kill tumor cells without prior sensitization or human leukocyte antigen (HLA) restriction. However, their efficacy is often limited by immune-evasion, especially major histocompatibility complex I (MHC-I)-mediated NK cell inhibition. NK cell engagers (NKCEs) can redirect NK cells to tumor for more effective immunotherapy, but most current NKCEs target tumor-associated antigens (TAAs), risking on-target, off-tumor toxicity in clinical applications. Neoantigens, as tumor-specific antigens (TSAs) arising from somatic mutations and presented by MHC-I on tumor cell surfaces, represent ideal tumor-specific target. Here, we engineered NKCEs built on neoantigen-targeting TCR-mimic antibodies (TCRm-Abs) to enhance tumor-specific NK cell-mediated cytotoxicity. Using a high-throughput hydrogel-based microwell single-cell chip (HMSC-chip) coupled with T2 cell-based de-selection, we identified C33-Ab, a functional TCRm-Ab specific for p53
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.